Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.25 USD
Change Today +0.10 / 0.76%
Volume 762.9K
VSAR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

versartis inc (VSAR) Snapshot

Open
$13.01
Previous Close
$13.15
Day High
$13.42
Day Low
$12.98
52 Week High
09/2/14 - $24.00
52 Week Low
08/24/15 - $12.46
Market Cap
388.9M
Average Volume 10 Days
240.2K
EPS TTM
$-2.63
Shares Outstanding
29.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERSARTIS INC (VSAR)

Related News

No related news articles were found.

versartis inc (VSAR) Related Businessweek News

No Related Businessweek News Found

versartis inc (VSAR) Details

Versartis, Inc., a development stage company, operates as an endocrine-focused biopharmaceutical company in the United States. The company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 3 clinical trials for the treatment of growth hormone deficiency. It develops drug candidates that it has licensed from Amunix Operating, Inc. The company was founded in 2008 and is headquartered in Menlo Park, California.

42 Employees
Last Reported Date: 08/5/15
Founded in 2008

versartis inc (VSAR) Top Compensated Officers

Co-Founder and Senior Scientific Advisor to t...
Total Annual Compensation: $410.0K
Chief Financial Officer
Total Annual Compensation: $305.0K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $270.0K
Compensation as of Fiscal Year 2014.

versartis inc (VSAR) Key Developments

Versartis, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Versartis, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $19,496,000 against $8,499,000 a year ago. Net loss attributable to common stockholders was $19,667,000 or $0.67 basic and diluted per share against $8,600,000 or $0.36 basic and diluted per share a year ago. For the six months, the company reported loss from operations of $41,777,000 against $16,082,000 a year ago. Net loss attributable to common stockholders was $41,673,000 or $1.60 basic and diluted per share against $53,585,000 or $3.95 basic and diluted per share a year ago.

Versartis, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 11:30 AM

Versartis, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 11:30 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Jay P. Shepard, Chief Executive Officer, President, Director, Member of Nominating and Corporate Governance Committee and Member of Compensation Committee.

Versartis Announces Removal of FDA Partial Clinical Hold and Continuation of VRS-317 Phase 3 Clinical Trial

Versartis, Inc. announced that the US Food and Drug Administration has removed the partial clinical hold on the company's Investigational new drug application for VRS-317. With this action, the company will proceed with the Phase 3 registration trial, VELOCITY, of VRS-317 in children with GHD. The company reaffirmed its previously stated anticipated milestones for the VELOCITY Phase 3 clinical trial, including interim 6-month mean height velocity data by the end of 2016 and top line data on the 12-month mean height velocity primary endpoint by mid-2017, enabling a potential Biologics License Application submission, followed by a potential FDA approval by late-2018.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSAR:US $13.25 USD +0.10

VSAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSAR.
View Industry Companies
 

Industry Analysis

VSAR

Industry Average

Valuation VSAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERSARTIS INC, please visit www.versartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.